Fuh, K. C., Secord, A. A., Bevis, K. S., Huh, W. K., Blansit, K., Rosenfeld, E., … Chan, J. K. (2015). Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? In Gynecologic Oncology (Vol. 137, pp. 56–56). Elsevier BV. https://doi.org/10.1016/j.ygyno.2015.01.130

Fuh, K. C., A. A. Secord, K. S. Bevis, W. K. Huh, K. Blansit, E. Rosenfeld, L. Hu, et al. “Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?” In Gynecologic Oncology, 137:56–56. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.130.

Fuh KC, Secord AA, Bevis KS, Huh WK, Blansit K, Rosenfeld E, et al. Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? In: Gynecologic Oncology. Elsevier BV; 2015. p. 56–56.

Fuh, K. C., et al. “Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?” Gynecologic Oncology, vol. 137, Elsevier BV, 2015, pp. 56–56. Crossref, doi:10.1016/j.ygyno.2015.01.130.

Fuh KC, Secord AA, Bevis KS, Huh WK, Blansit K, Rosenfeld E, Hu L, Previs RA, Gardner AB, Kapp DS, Chan JK. Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? Gynecologic Oncology. Elsevier BV; 2015. p. 56–56.